New data suggest that Strattera? (atomoxetine HCl) improved ADHD symptoms in children and adolescents who had both ADHD and a reading disorder, like dyslexia. Results were announced at a meeting of child and adolescent psychiatrists.
World Health Organization (WHO) and a group of more than 25 partner organizations unveiled a new strategy to fight some of the most neglected tropical diseases that destroy the lives and health of poor people.
Merck & Co., Inc. announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend that adults 60 years of age and older be vaccinated with ZOSTAVAX? [Zoster Vaccine Live (Oka/Merck)] to help prevent shingles (herpes zoster), a frequently painful disease marked by a blistering rash.
The Food and Drug Administration (FDA) announced the approval of Omnaris (ciclesonide) nasal spray, a new drug for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis, commonly known as hay fever, in adults and children 12 years of age and older.
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new 300 mg single capsule formulation of REYATAZ? (atazanavir sulfate) for the treatment of HIV-1 infection in adults as part of combination therapy. Taken once daily along with ritonavir and food as part of a anti-HIV drug regimen, the REYATAZ 300 mg single capsule formulation can replace two REYATAZ 150 mg capsules for: patients who have previously received anti-HIV medicines, patients who will be receiving tenofovir disoproxil fumarate, and patients who have never taken anti-HIV medicines that require SUSTIVA? (efavirenz) as part of their anti-HIV drug regimen. The REYATAZ single capsule formulation will be available in the United States within seven business days.
Nosodes is a term derived from the Greek word NOSO ? which signifies the prefix added to the word to form an idea of disease or indicating a relation to the disease.
Mrs. A. R., Age: 46 years., visited on 28-05-2005. The patient was suffering from severe pain in her right hip joint since 6th April, 2005. The patient was admitted in a well equipped hospital on 12 – 4 – 2005, where she was treated till 6 – 5 – 2005. In the hospital she was found to be suffering from various complications/diseases such as jaundice, bilateral pleural effusion, high count of leucocytes, hepatomegaly and cholelithiasis etc. She was treated accordingly for these complaints/diseases. Her blood samples were tested daily there are 42 blood reports in a span of 25 days, Ultrasound scanning and echocardiography with color Doppler study were also done. Lot of medication was done and was discharged from the hospital with not a feather of relief in her pain of right hip joint for which she was admitted. When seen on 28 – 5 – 2005 her condition was as described hereunder:
The Food and Drug Administration (FDA) licensed Zostavax, on May 25, 2006, a new vaccine to reduce the risk of shingles (herpes zoster) for use in people 60 years of age and older.
1. – Painfulness and violent burning, shooting pains in spinal column.
1. – Dread of death when alone, or on going to bed; great restlessness and utter prostration.